正常大鼠和六氯苯卟啉症大鼠的肝脏亚铁螯合酶。药物作用机制。

Liver ferrochelatase from normal and hexachlorobenzene porphyric rats. Mechanism of drug action.

Ríos de Molina M C, Billi de Catabbi S, San Martín de Viale L C

Departamento de Química Biológica, Faculted de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Argentina.

Int J Biochem. 1991;23(7-8):669-73. doi: 10.1016/0020-711x(91)90036-m.

Abstract

The action of hexachlorobenzene (HCB) on hepatic ferrochelatase was investigated. 2. A direct action of HCB, pentachlorophenol, porphyrins and haem on this enzyme activity was discarded. 3. In HCB porphyric liver there is probably an activator tightly bound to the enzyme. 4. Pyridoxal phosphate (PPL) may be a cofactor of ferrochelatase from both normal and porphyric rats. 5. The PPL would be involved in the binding site of Fe2+ or at least in the approaching of Fe2+ to the active site of the enzyme. 6. The differences found between normal and porphyric preparations could be attributed to conformational changes elicited by the HCB.

摘要

研究了六氯苯（HCB）对肝铁螯合酶的作用。2. 排除了HCB、五氯苯酚、卟啉和血红素对该酶活性的直接作用。3. 在HCB致卟啉症的肝脏中，可能存在一种与该酶紧密结合的激活剂。4. 磷酸吡哆醛（PPL）可能是正常大鼠和患卟啉症大鼠铁螯合酶的辅因子。5. PPL可能参与Fe2+的结合位点，或至少参与Fe2+接近酶的活性位点。6. 在正常制剂和卟啉症制剂之间发现的差异可能归因于HCB引起的构象变化。